Replimune Group, Inc. REPL
Set alert
17.61 USD +0.22 +1.27%
At close
17.68 +0.07 +0.38%
Pre-market · Nov 2, 8:09 AM ET
16.64 Day range 18.27
1.50 52-week range 18.27
- YTD
- +81.17%
- 1 year
- +80.99%
- Open
- 17.49
- Prev close
- 17.39
- Mkt cap
- 1.67B
- Vol
- 3.85M
- Avg vol
- 3.01M
- EPS
- -2.79
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 16.64
- High
- 18.27
- Forward P/E
- -27.19
- Beta
- 0.00
- Short ratio
- 11.50
- Inst. own
- 105.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 2, 2027
- 50-d avg
- 13.51
- 200-d avg
- 9.24
- 1y target
- 23.33
6M chart
Events in this range
- Jun 29, 2026Earnings: -0.76; estimate -0.73; surprise -4.11%
- Jul 31, 2026Rating: Wedbush · Neutral → Neutral
- Aug 4, 2026Rating: Leerink Partners · Market Perform → Outperform
- Aug 7, 2026Rating: Wedbush · Neutral → Outperform
- Aug 7, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 14, 2026Earnings: -0.72; estimate -0.694; surprise -3.75%
- Aug 26, 2026Rating: JP Morgan · Overweight → Overweight
- Oct 28, 2026Earnings: -0.54; estimate -0.784; surprise 31.12%
- Oct 29, 2026Rating: Leerink Partners · Outperform → Outperform
Signals (31)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| RSI: Overbought | Oct 28, 2026 | 4 days ago |
| SMA: Bullish | Oct 26, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| RSI: Oversold | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| RSI: Overbought | Jul 2, 2026 | 4 months ago |
| MACD: Sell Signal | Jul 1, 2026 | 4 months ago |
| RSI: Overbought | Jun 18, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 16, 2026 | 4 months ago |
| SMA: Bullish | May 29, 2026 | 5 months ago |
| RSI: Overbought | May 29, 2026 | 5 months ago |
| SMA: Bearish | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bullish | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
Discussion (20)
Sign in to join the discussion
Mark REPL 2 months ago #1IOVA is king.
Mark REPL 2 months ago #2Sold and loaded the boat with IOVA shares. Good luck.
Mark REPL 3 months ago #3Wow that was close 10000 shares sold.
Mark REPL 3 months ago #4Sold the news leaked on Reddit.
Mark REPL 3 months ago #5Volume is low.. not good..
However, if Dr. Richard Pazdur returns to lead the FDA, the impact on Iovance Biotherapeutics (IOVA) is expected to be highly favorable, particularly for its long-term oncology pipeline.
A potential return of Dr. Richard Pazdur to the FDA is widely seen as bad news for REPL because he is historically the primary reason their melanoma drug was rejected.
$REPL @TILS KILLS CANCER ?? Today is Monday, dummy
$REPL ?? Oh SHIT! ? Its gonna take off
Today the Earnings Date for $REPL ???